About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

188.88 -14.33 (-7.05%)
Delayed Quote Updated: 10:26 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Monday's pre-market session: top gainers and losers in the S&P500 index ↗
Via Chartmill
Wall Street Got the Weak Jobs Report It Wanted. Chip Stocks Wrecked the Rally Anyway. ↗
Via Chartmill
News headline image
MarketBeat Week in Review – 06/29 - 07/03 ↗
MarketBeat's weekly roundup covers a weaker June jobs report, tech sector rotation, and top analyst picks including TSLA, AVGO, PLTR, MRNA, and NEE heading into Q2 earnings season. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives? ↗
When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong. 
Via The Motley Fool
News headline image
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? ↗
Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles. 
Via The Motley Fool
News headline image
3 Cash-Heavy Stocks with Warning Signs
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
Via StockStory
Topics Artificial Intelligence
News headline image
Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its pe... 
Via StockStory
Topics Artificial Intelligence
Thursday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
Short Squeeze Alert—Moderna Stock Surges on New Strategy ↗
Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines faces a multi-year path to revenue. 
Via MarketBeat
News headline image
Is Moderna Stock a No-Brainer Buy After a Key FDA Win? ↗
Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock. 
Via The Motley Fool
News headline image
Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers. ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers. Over th... 
Via StockStory
Topics Artificial Intelligence
Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side ↗
Via Chartmill
Discover which S&P500 stocks are making waves on Friday. ↗
Via Chartmill
Friday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst ↗
It's not just a "pandemic stock," after all. 
Via The Motley Fool
News headline image
Moderna Science Day Highlights Expanding Potential of mRNA Platform
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
Which S&P500 stocks are moving on Tuesday? ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q1 therapeutics earnings season. Over the next ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Should You Buy Moderna Before Aug. 5? ↗
Moderna just received fantastic news. 
Via The Motley Fool
Monday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
Which S&P500 stocks are gapping on Monday? ↗
Via Chartmill
News headline image
Q1 Earnings Outperformers: United Therapeutics (NASDAQ:UTHR) And The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence
News headline image
Moderna Has Some Key Approvals Ahead. Is the Stock a Buy? ↗
The company's pending vaccine approvals could help the stock continue its rise. 
Via The Motley Fool
News headline image
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
From Moderna, Inc.
Via ACCESS Newswire
News headline image
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead ↗
They haven't peaked yet. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.